Sign In
6 Jun 2013 14:32

For immediate release | 6 June 2013 |
Â
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Â
Share Options
Â
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that on 6 June 2013 it awarded the following options over ordinary shares of the Company to certain Directors.
Â
Â
Name | Position | Number of share options awarded | Exercise price per share | Date of vesting | Percentage of issued ordinary share capital |
Tony Booley | Executive Director | 144,200 | 37.25p | 6 June 2016 | 0.06% |
Peter Butterfield  | Executive Director | 144,200 | 37.25p | 6 June 2016 | 0.06% |
Richard Wright | Finance Director | 144,200 | 37.25p | 6 June 2016 | 0.06% |
Â
Â
For further information:
Â
Alliance Pharma plc | + 44 (0) 1249 466966 |
John Dawson, Chief Executive | |
Richard Wright, Finance Director | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles | |
Numis Securities Limited | + 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Oliver Cardigan / Freddie Barnfield | |
Corporate Broking: David Poutney |
Â
Notes to editors:
Â
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.
Â
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
Follow the stocks
